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DNA mismatch repair (MMR) ensures replication
fidelity by correcting mismatches generated during
DNA replication. Although human MMR has been
reconstituted in vitro, how MMR occurs in vivo is
unknown. Here, we show that an epigenetic histone
mark, H3K36me3, is required in vivo to recruit the
mismatch recognition protein hMutSa (hMSH2-
hMSH6) onto chromatin through direct interactions
with the hMSH6 PWWP domain. The abundance of
H3K36me3 in G1 and early S phases ensures that
hMutSa is enriched on chromatin before mispairs
are introduced during DNA replication. Cells lacking
the H3K36 trimethyltransferase SETD2 display
microsatellite instability (MSI) and an elevated spon-
taneous mutation frequency, characteristic of MMR-
deficient cells. This work reveals that a histone mark
regulates MMR in human cells and explains the long-
standing puzzle ofMSI-positive cancer cells that lack
detectable mutations in known MMR genes.INTRODUCTION
DNA mismatch repair (MMR) maintains genome stability pri-
marily by correcting base-base and small insertion-deletion (ID)
mispairs generated during DNA replication (Kolodner, 1996;
Kunkel and Erie, 2005; Li, 2008; Modrich and Lahue, 1996). In
human cells, these mispairs are recognized by hMSH2-hMSH6
(hMutSa) and hMSH2-hMSH3 (hMutSb). Normally, cells express
more hMSH6 than hMSH3, leading to a hMutSa:hMutSb ratio of
10:1 (Drummond et al., 1997; Marra et al., 1998). Despite their
redundant activities in mismatch recognition, both complexes
are required for MMR, and defective or abnormal expression of
hMSH6 or hMSH3 leads to a mutator phenotype (Drummond
et al., 1995, 1997; Harrington and Kolodner, 2007; Marsischky
et al., 1996). Previous studies have shown that genetic and
epigenetic modifications that impair the expression of these590 Cell 153, 590–600, April 25, 2013 ª2013 Elsevier Inc.and other MMR genes, especially hMSH2, hMSH6, and
hMLH1, cause susceptibility to certain types of cancer, including
hereditary nonpolyposis colorectal cancer (HNPCC) (Fishel and
Kolodner, 1995; Kane et al., 1997; Modrich and Lahue, 1996).
At the cellular level, defects in MMR cause a mutator pheno-
type, which can be readily detected in eukaryotic cells as insta-
bility in simple repetitive DNA sequences called microsatellites.
Thus, microsatellite instability (MSI) is regarded as a hallmark
of MMR deficiency (Kolodner, 1996; Kunkel and Erie, 2005; Li,
2008; Modrich and Lahue, 1996). However, a significant fraction
of MSI-positive colorectal cancers express MMR genes at
normal levels and do not carry a detectable mutation in or hyper-
methylation of known MMR genes (Peltoma¨ki, 2003). Similarly,
certain noncolorectal cancer cells with MSI also appear to
be proficient in MMR (Gu et al., 2002; Wang et al., 2011). The
molecular mechanism underlying MSI in these cases is obscure.
The MMR capacity of mammalian cells has typically been
evaluated using a functional assay that measures in vitro repair
of a naked model DNA heteroduplex (Holmes et al., 1990;
Thomas et al., 1991; Zhang et al., 2005). This assay has helped
identify MMR defects in HNPCC and other MSI-positive cancers
(Parsons et al., 1993; Umar et al., 1994) and has been invaluable
in characterizing the MMR pathway in human cells in great
molecular detail (reviewed by Li, 2008). However, increasing
evidence suggests that a mismatch assembled into nucleo-
somes is a poor substrate for the in vitro MMR system. Li et al.
(2009) showed that nucleosomes derived from recombinant his-
tones and amismatch-containing DNA diminished the mismatch
binding and ATPase and DNA sliding activities of hMutSa, which
are required for MMR. Scho¨pf et al. (2012) demonstrated that
hMutSa failed to restore MMR to an hMSH6-deficient nuclear
extract when DNA heteroduplexes were assembled into nucleo-
somes by preincubating with the extract. These observations
suggest that additional factors and/or mechanisms are needed
for MMR in vivo, possibly by disrupting nucleosomes or the
timely recruiting of MMR proteins, or both. Consistent with this
hypothesis, histone modifications and chromatin remodeling
factors have been implicated in MMR (Javaid et al., 2009;
Kadyrova et al., 2011), and MMR has been show to couple
with DNA replication (Hombauer et al., 2011a; Simmons
Figure 1. The PWWPDomain and Structural
Models for Interaction with H3K36me3
(A) Domain structure of hMSH6 and sequence
alignment of PWWP modules. Upper panel shows
the domain structure of hMSH6. PIP, PCNA-
interacting protein motif; NLS, nuclear localiza-
tion signal. Lower panel shows alignment of
representative human PWWP domains. The blue
dots indicate residues that form an aromatic
cage and bind to H3K36me3. Aligned proteins
are hMSH6, BRPF1, WHSC1_N, WHSC1_C,
ZDWPW1, and HDGF.
(B) Interactions between PWWP domains and the
H3K36me3-containing H3 peptide. The crystal
structure of BRPF1 PWWP domain bound to the
H3K36me3 peptide (Protein Data Bank [PDB] ID
code 2X4Y) is shown in the left panel. BRPF1 does
not have the Trp residues and instead contains a
PSYP sequence (shown in yellow). The structure of
the hMSH6 PWWP domain, which has the
authentic PWWP motif, was determined by
nuclear magnetic resonance (Laguri et al., 2008) in
the absence of an H3 peptide (PDB ID code
2GFU). The H3 peptide in the BRPF1 complex is
shown with human hMSH6 (right panel) after
superimposing the conserved PWWP domains of
the two proteins. The aromatic cage (colored blue)
encloses the trimethylated Lys. The rotamer con-
formations ofW106 and F133 in hMSH6 likely have
to adjust upon binding of the H3K36me3.et al., 2008), during which nucleosomes are disrupted. More
strikingly, the hMSH6 subunit of hMutSa contains a Pro-Trp-
Trp-Pro (PWWP) domain (Laguri et al., 2008), and this domain,
which is present in many chromatin-associated proteins, was
recently identified as a ‘‘reader’’ of trimethylated Lys36 in histone
3 (H3K36me3) (Dhayalan et al., 2010; Vermeulen et al., 2010;
Vezzoli et al., 2010). However, it is not yet known whether the
H3K36me3 mark plays a role in MMR.
Here, we demonstrate that H3K36me3 interacts specifically
with the hMSH6 PWWP domain of hMutSa in vitro and in vivo
and that the histone methyltransferase SETD2, which is respon-
sible for trimethylation of H3K36 (Edmunds et al., 2008), is
required for human MMR in vivo. Consistent with this, cells
depleted of SETD2 and H3K36me3 display a mutator phenotype
characterized by MSI and an elevated mutation frequency at the
HPRT locus. The data presented here strongly suggest that
the H3K36me3 histone mark regulates human MMR in vivo by
recruiting hMutSa onto chromatin to be replicated. We therefore
propose that the status of H3K36me3 in a specific gene or inter-
genic region could potentially influence the local mutation rate in
that region of the chromosome.
RESULTS
The hMSH6 PWWP Domain Interacts with H3K36me3
and Is Essential for hMutSa Binding to Chromatin
The hMSH6 subunit of hMutSa contains a PWWPdomain (Laguri
et al., 2008), and this conserved domain has recently been pro-
posed to interact specifically with H3K36me3 (Dhayalan et al.,
2010; Vermeulen et al., 2010; Vezzoli et al., 2010). Figure 1A
shows an alignment of the hMSH6 PWWP domain with five otherPWWP domains, including that of BRPF1, the only PWWP
domain for which an atomic resolution structure of the complex
with H3K36me3 is available (Vezzoli et al., 2010; Wu et al., 2011).
Interestingly, the cocrystal structures of the BRPF1 PWWP and
H3K36me3 peptide (Vezzoli et al., 2010; Wu et al., 2011) indicate
that three residues in the PWWP domain form an aromatic cage
surrounding the H3K36me3 (Figure 1B, left). Consistent with this,
our alignment of PWWP domains shows that the proposed
‘‘cage’’ residues are highly conserved (Figure 1A, blue dots).
Based on these data, we generated a model of hMSH6 bound
to the H3K36me3 peptide (Figure 1B, right) by superimposing
the PWWP domains of hMSH6 and BRPF1 (Laguri et al., 2008).
The above data prompted us to ask whether the H3K36me3
mark modulates the interaction between hMutSa and chromatin
and whether such an interaction involves the hMSH6 PWWP
domain. To answer these questions, a glutathione S-transferase
(GST) fusion protein including hMSH6 residues 89 to 194 was
used to pull down histone octamers isolated from HeLa cells
(carrying ‘‘native’’ histone modifications) or assembled using
recombinant histones. The results show that the hMSH6
PWWP domain efficiently pulls down histone octamers from
HeLa cells, but it pulls down recombinant histone octamers
with very low efficiency (Figure 2A). This suggests a specific
interaction between the hMSH6 PWWP domain and an epi-
genetic histone signature.
The specificity of the interaction between the hMSH6 PWWP
domain and natively modified octamers was examined by the
following experiments. First, the same pull-down assay was
performed using native histone octamers purified from HeLa
cells (Rodriguez-Collazo et al., 2009) and wild-type or a mutant
hMSH6 PWWP fusion protein in which W105 and W106 areCell 153, 590–600, April 25, 2013 ª2013 Elsevier Inc. 591
Figure 2. The MSH6 PWWP Domain Interacts with Histone Octamers Containing H3K36me3
(A) GST pull-down assay for interaction of wild-type GST-PWWP peptide with native histone octamer (purified from HeLa cells) or recombinant histone octamer.
Unless otherwise mentioned, octamer marked with asterisk in this figure was detected by staining with Coomassie blue, and proteins not marked were detected
by silver staining or western blot using antibodies against the indicated components.
(B) GST pull-down assay for interaction between the native histone octamer and recombinant wild-type (WT) or mutant (PAAP) PWWP peptide.
(C) hMutSa pull-down assay by biotin-labeled H3 peptides containing various forms of methylation in K36, as indicated. Bound hMutSawas eluted and detected
by an hMSH6 antibody. Relative hMutSa binding was determined using the level of hMutSa in the K36me3 peptide-containing reaction as a reference.
(D) Interaction of H3 peptide containing K36me3 with hMutSa with wild-type or a mutant PWWP domain, as indicated. The experiment was performed as in (C).
(E) Recombinant histone H3with a chemically installed analog of trimethyllysine at position 36 (H3Kc36me3/Kc36me3) forms histone octamers with other histone
proteins (i.e., H2A, H2B, and H4) as efficient as recombinant wild-type histone H3 (K36).
(F) Coimmunoprecipitation of histone octamer containing H3Kc36me3 and hMutSa with wild-type (WT) or mutant (PAAP) PWWP domain. hMSH2 antibody was
used for pull down. The presence of H3Kc36me3 in the pull-down was detected using an H3K36me3-specific antibody.replaced by two alanines (PAAP), and the histone octamers
bound to the GST fusion proteins were detected by an
H3K36me3-specific antibody. As shown in Figure 2B, wild-
type (WT), but not the mutant, GST-hMSH6 PWWP selectively
binds native histone octamers containing H3K36me3. Similar
results were also obtained with a PWWP mutant containing an
Y103A mutation (data not shown). Second, when H3 peptides
containing no, mono-, di-, or trimethylated K36 were incubated
with hMutSa in the pull-down assay (Figure 2C), little interaction
was detected between hMutSa and the peptide containing no
(K36) or mono- (K36me1) methylations, but hMutSa was pulled
down by di- (H3K36me2) and tri- (K36me3) methylated peptides,
with approximately 5-fold more hMutSa coprecipitating with
trimethylated peptide than with dimethylated peptide. These
results suggest that hMutSa preferentially binds to H3K36me3.
In the following experiments, the interaction between the
trimethylated peptide from H3 and several PWWP-mutated
hMutSa variants was examined. One mutant hMutSa contained
a PAAP motif (hMutSa[PAAP]) instead of the PWWP motif, and
another had a deletion of the first 340 amino acid residues
(D340), including the PWWP domain, in hMSH6 (hMutSa
[D340]). As shown in Figure 2D, the H3K36me3 peptide pulled
down wild-type hMutSa but did not pull down PWWP-deficient
hMutSa proteins. Finally, coimmunoprecipitation was performed
to confirm the interaction between the hMutSa PWWP domain
and the H3K36me3-containing histone octamer. Here, recom-592 Cell 153, 590–600, April 25, 2013 ª2013 Elsevier Inc.binant histone H3 with an analog of trimethylated K36
(Kc36me3) (Simon et al., 2007) was used to assemble histone
octamers; the octamers were recognized by antibody specific
to H3K36me3 (Figure 2E), indicating that H3Kc36me3 is a struc-
tural mimic of H3K36me3. The resulting H3Kc36me3 octamers
were then incubated with hMutSa or hMutSa[PAAP]. As shown
in Figure 2F, hMSH2 antibody only coimmunoprecipitated
wild-type hMutSa and H3Kc36me3-containing octamers. Thus,
these data support the idea that the hMSH6 PWWP domain
interacts specifically with trimethylated H3K36 in vitro and sug-
gest that a similar specific interaction between hMutSa and
H3K36me3 might occur on chromatin in vivo.
PWWP Domain Is Dispensable for MMR In Vitro but
Essential for hMSH6 Interaction with Chromatin
The role of the hMSH6 PWWP domain in MMR was tested by
analyzing the ability of wild-type hMutSa or PWWP-deficient
hMutSa to restore MMR to a nuclear extract from a hMSH2-
deficient leukemia cell line, NALM6 (Gu et al., 2002), using a
functional in vitro assay (Zhang et al., 2005). Surprisingly, both
PWWP-deficient proteins, hMutSa[PAAP] and hMutSa[D340],
could efficiently restore MMR to NALM6 extracts (Figure 3A),
suggesting that the hMSH6 PWWP domain is not essential for
MMR in vitro.
The role of the hMSH6 PWWP domain in localizing hMSH6
to chromatin was examined in hMSH6-deficient DLD-1 cells
Figure 3. The Role of hMSH6 PWWP
Domain and Its Interaction with H3K36me3
in MMR
(A) In vitro MMR assay to determine hMutSa with
wild-type (WT) or a mutant (PAAP or D340) PWWP
domain for its ability to restore MMR to hMSH2-
deficient NALM6 nuclear extracts as described
previously (Zhang et al., 2005). HeLa nuclear
extracts (HL) were used as a positive control.
Arrows indicate repair products.
(B) Fluorescence imaging of cells expressing
EGFP-hMSH6 containing WT or a mutant PWWP
domain in hMSH6-deficient DLD-1 cells in S
phase.
(C) Number of hMSH6 foci per nucleus in DLD-1
cells transfected with EGFP-hMSH6 containing
WT or a mutant PWWP domain. The ‘‘n’’ value
indicates the total number of nuclei analyzed in a
given case. The error bars represent SD.
(D) Western blot analysis showing the expression
of the indicated proteins in DLD-1 cells stably
transfected with a scrambled shRNA (control) or a
SETD2-specific shRNA.
(E) Fluorescence imaging of SETD2 knockdown
or control DLD-1cells expressing wild-type EGFP-
hMSH6 in S phase.expressing enhanced green fluorescent protein (EGFP)-tagged
wild-type or mutant hMSH6. Three hMSH6 mutants were
generated, which contained alanine substitutions at the aromatic
cage residues W105 and W106 (PAAP), Y103 (Y103A), or F133
(F133A). DLD-1 cells expressing EGFP-tagged wild-type
hMSH6, hMSH6(Y103A), hMSH6(PAAP), or hMSH6(F133A)
were arrested in S phase and then analyzed by fluorescent
confocal microscopy. The results show that hMSH6 clearly
formed foci in cells expressing wild-type hMSH6, but signifi-
cantly (p < 0.001) fewer hMSH6 foci were found in cells ex-
pressing the mutant hMSH6 proteins (Figures 3B and 3C);
instead, fluorescence remained evenly distributed in the
nucleus in the latter cells (Figure 3B). Together with the data
shown in Figures 1 and 2, these observations imply that the
hMSH6 PWWP domain, although not required for MMR
in vitro, is required to recruit hMSH6 to chromatin. This sup-
ports the idea that the hMSH6 PWWP domain ‘‘reads’’ the
H3K36me3 mark.
H3K36me3 Facilitates Localization of hMutSa
to Chromatin In Vivo
SETD2 is a methyltransferase responsible for H3K36 trimethyla-
tion (Duns et al., 2010; Edmunds et al., 2008; Yoh et al., 2008). To
determine if hMSH6 chromatin localization relies on H3K36me3,
we performed SETD2 knockdown by short hairpin RNA (shRNA)
in DLD-1 cells, which apparently led to a targeted depletion of
SETD2, as the same vector containing a scrambled shRNA
(control) did not reduce expression of SETD2 (Figure 3D). As
expected, the SETD2 knockdown cells expressed a low level
of H3K36me3 (Figure 3D). Interestingly, hMSH6 formed distinct
foci in control DLD-1 cells, but it formed fewer foci and was
distributed more evenly within the nucleus in shSETD2-DLD-1
cells (Figure 3E). These results suggest that H3K36me3
influences the distribution of hMSH6 in chromatin.This idea was further tested with the endogenous hMSH6 in
MMR-proficient HeLa cells with or without a targeted SETD2
knockdown by shRNA (Figure 4A). After synchronization of
control HeLa (transfected with a scrambled shRNA) and
SETD2-depleted HeLa in S or G2/M phases, chromatin localiza-
tion of endogenously expressed hMSH6 was monitored by
immunofluorescence using an antibody to hMSH6. The results
show that during S phase, significantly fewer hMSH6 foci were
observed in the SETD2/H3K36me3-depleted HeLa cells than in
control HeLa cells (Figures 4B and 4C), further supporting the
idea that localization of hMSH6 to chromatin is facilitated by
H3K36me3. In addition, 70% of hMSH6 foci appeared to
colocalize with H3K36me3 in control HeLa cells, but not in
SETD2/H3K36me3-depleted cells (Figure 4B). Similar results
were also obtained using an antibody to hMSH2 (Figure S1A
available online), indicating that the effect is for the whole
hMutSa complex. These results were confirmed in another
HeLa clone, whose SEDT2 was stably knocked down by a
second SETD2 shRNA (Figure S1B). Interestingly, the number
of hMSH6 foci (Figures 4B and 4C) was very low in control
G2/M HeLa cells. However, this has nothing to do with the
amount of hMSH6 in these cells because hMSH6 in G2/M is as
abundant as in other cell-cycle phases (Figures 4D and 4E).
To determine if this phenomenon is directly correlated with the
abundance of H3K36me3, H3K36me3 and H3 were quantified in
HeLa cells arrested at different stages of the cell cycle. The re-
sults show that H3K36me3 reaches a maximum abundance in
early S phase, declines to a very low level by the end of S phase
and G2/M, and begins to increase in abundance in G1, even
though the amount of histone H3 is relatively constant
throughout the cell cycle (Figures 4D and 4E). We also observed
abundant hMSH6 foci and their partial (80%) colocalization
with H3K36me3 in G1 phase (Figure S1C). Together, these re-
sults suggest that H3K36me3 recruits hMutSa to chromatinCell 153, 590–600, April 25, 2013 ª2013 Elsevier Inc. 593
Figure 4. SETD2/H3K36me3 Depletion
Alters hMSH6 Nuclear Localization
(A) Western blot analysis showing the expression
of the indicated proteins in HeLa cells stably
transfected with a scrambled shRNA (control) and
two different SETD2-specific shRNAs (SETD2).
(B) hMSH6 and H3K36me3 foci formation and
colocalization in control- and shSETD2-HeLa cells
in S or G2/M phase.
(C) The number of hMSH6 foci per nucleus in
control- and shSETD2-HeLa cells. The ‘‘n’’ value
indicates the total number of nuclei analyzed in a
given case. The error bars represent SD.
(D) Western blot analysis showing the abundance
of hMSH6 andH3K36me3 in G1, S, or G2/M phase
in control HeLa cells. S phase was divided into
early (E), middle (M), and late (L) subphases.
(E) Quantification of hMSH6 or H3K36me3
expression in different cell-cycle phases from
three independent western blots. The intensity of
each protein in G1 was used as a reference after
correction for loading (i.e., the intensity of tubulin).
The error bars represent SD.
See also Figures S1 and S2.in vivo before and during early S phase, which could increase the
efficiency of MMR in actively replicating chromatin.
Although the interaction between hMSH6 and chromatin
appears to be facilitated by H3K36me3, not all hMSH6 foci
colocalize with H3K36me3 foci in S phase HeLa cells (Figures
4B). These results may suggest one or both of the following
possibilities: (1) not all H3K36me3 marks recruit hMutSa, and
(2) after binding, hMutSa disassociates from H3K36me3 during
DNA replication, possibly because of specific interactions with
the replication machinery, as previously reported (Hombauer
et al., 2011a; Kleczkowska et al., 2001) (see Discussion for
more details).
To further determine that the H3K36me3-PWWP interaction is
specific for recruiting hMSH6, we measured nuclear distribution
of the hMSH3 subunit of hMutSb and its colocalization with
H3K36me3. We show that hMSH3, which lacks a PWWP
domain, does not interact with H3K36me3, and its nuclear local-
ization is independent of H3K36me3 (Figure S2), consistent with
the notion that human cells utilize different mechanisms for
hMutSa and hMutSb recruitments (Hong et al., 2008).
HeLa Cells with SETD2 Knockdown Display a Mutator
Phenotype
As suggested above, if the hMSH6-H3K36me3 interaction
recruits hMutSa to chromatin in vivo, then it could be essential
for MMR in vivo. If this prediction is correct, cells lacking or
depleted for H3K36me3 will be MMR-deficient and have an
increased mutation frequency. To explore this prediction,
control and SETD2-depleted HeLa cells were tested for MSI
at four microsatellite loci as described previously (Parsons
et al., 1993). The results (Figure 5A) show no MSI in control
HeLa cells, whereas 4 out of 14 (28.6%) subclones from
SETD2/H3K36me3-depleted HeLa cells showed either new594 Cell 153, 590–600, April 25, 2013 ª2013 Elsevier Inc.microsatellite species (asterisk) or deletion of a microsatellite
mark (D). As a positive control, MSI was also analyzed in
hMSH6-deficient DLD-1 cells, and the results show new repeat
species in 6 out of 15 (40%) subclones (Figure S3). Despite a
difference in the percentage of subclones showing new repeat
species, the data clearly demonstrate that like hMSH6-
deficient DLD-1 cells, SETD2/H3K36me3-depleted HeLa cells
display MSI.
To further confirm the mutator phenotype in SETD2/
H3K36me3-depleted cells, we measured the spontaneous
forward mutation frequency in the hypoxanthine-guanine phos-
phoribosyltransferase (HPRT) gene (Kat et al., 1993) in SETD2/
H3K36me3-depleted and control HeLa cells. As shown in
Figure 5B, the spontaneous mutation frequency in SETD2/
H3K36me3-depleted HeLa cells had an 18-fold increase
(1.2 3 105, p < 0.05) compared to that in control HeLa cells
(6.93 107), indicating that SETD2/H3K36me3 depletion causes
a mutator phenotype. When the same analysis was performed in
hMSH6-deficient shSETD2-DLD-1 and control DLDL-1 cells, the
mutation frequency essentially remained unchanged (Figure 5B).
This result suggests that SETD2 depletion only alters the muta-
tion frequency in hMSH6-competent cells, which is consistent
with the idea that H3K36me3 recruits hMutSa. Interestingly,
the mutation frequency in SETD2/H3K36me3-depleted HeLa
cells is10-fold lower than that in hMSH6-deficient DLD-1 cells,
which is likely due to both the efficiency of SETD2 depletion and
the huge difference in the total passage number between these
two cells. In addition, H3K36me3 may not be the only mecha-
nism for hMSH6 recruitment.
To determine if SETD2/H3K36me3 modulates the enzymatic
function(s) of MMR proteins, the in vitro MMR activity of
SETD2/H3K36me3-depleted HeLa cells was examined. Consis-
tent with our model (see below), these cells are not defective in
Figure 5. SETD2-Deficient HeLa Cells Display a Mutator Phenotype
(A) Analysis of PCR product patterns of four microsatellite markers in sub-
clones derived from control- and shSETD2-HeLa cells. The black D or asterisk
shows the clone exhibiting deletion of a repeat mark or new repeat species,
respectively.
(B) HPRT mutability in control- and shSETD2-HeLa and DLD-1 cells. Data are
presented as mean ±SD. Fold increase in mutation frequency was calculated
using the mutation frequency of control HeLa as a reference, and a t test was
used to determine the p value.
(C) In vitro MMR assay using nuclear extracts isolated from control- and
shSETD2-HeLa cells.
See also Figure S3.MMR in vitro (Figure 5C). This observation indicates that SETD2
and H3K36me3 are not physically involved in MMR and that
depletion of SETD2/H3K36me3 does not alter the expression
or function of MMR genes.
Cancer Cells Deficient in SETD2 Display MSI and Fail
to Recruit hMutSa to Chromatin
Recent studies identified SETD2 as a tumor suppressor for clear
cell renal cell carcinoma (ccRCC) (Dalgliesh et al., 2010; Duns
et al., 2010; Gerlinger et al., 2012; Varela et al., 2011), but the
mechanism linking SETD2 deficiency to ccRCC tumorigenesis
remains unknown. We hypothesize that defective MMR may
contribute to tumorigenesis in SETD2-deficient ccRCC patients.
To test this hypothesis, we screened several ccRCC cell lines for
SETD2 mutations and identified a SETD2-deficient ccRCC cell
line, UOK143, which carries A5197 / G and T5306 / C muta-
tions, leading to N1734D and S1769P amino acid substitutions
in SETD2, respectively (Figure S4A). Western blot analysis
shows that UOK143 cells express undetectable amounts of
SETD2, which is readily detected in the SETD2-proficient ccRCC
cell line, UOK121 (Figure 6A). As expected, the amount of
H3K36me3 is much lower in UOK143 cells than in UOK121 cells
(Figure 6A). We then analyzed the distribution of hMSH6 and
H3K36me3 in these ccRCC cells. H3K36me3 was barely detect-
able in UOK143 cells by immunofluorescence but was relatively
more abundant in UOK121 cells (Figure 6B). Correspondingly, in
S phase UOK121 cells, hMSH6 foci were abundant and partially
(70%) colocalized with H3K36me3, whereas significantly fewerand smaller hMSH6 foci were observed in S phase UOK143
cells (Figures 6B and 6C), which is similar to what was observed
in SETD2/H3K36me3-depleted HeLa (Figure 4B) and DLD-1
(Figure 3E) cells. As noted previously, these results suggest
that H3K36me3 facilitates localization of hMSH6 (hMutSa) to
chromatin.
To determine if the failure to recruit hMutSa confers an MMR-
deficient phenotype to UOK143 cells, we examined MSI in
UOK143 and UOK121 cells. The results revealed no MSI in
UOK121 cells and that UOK143 cells exhibited mono- and dinu-
cleotide repeat instability, as all subclones, except clone 1,
exhibit either new repeat species or deletion of a microsatellite
marker (Figure 6D). To rule out the possibility that UOK143 cells
carry a defective MMR component, we measured in vitro MMR
activity of UOK143 and UOK121, observing the same normal
levels of MMR activity and proteins in extracts from both cell
lines (data not shown). These results suggest that MSI in
UOK143 cells is caused by loss of SETD2 activity, not loss of
MMR capacity.
We previously characterized a Burkitt’s lymphoma cell line,
NAMALWA, that displays MSI but is proficient in MMR in vitro
(Gu et al., 2002). We therefore analyzed if this cell line is defective
in SETD2. The result shows that NAMALWA cells carry a hetero-
zygous deletion of exon 8 in SETD2 (Figure S4B), which also
alters the reading frame of the gene. Consistent with this result,
NAMALWA cells express a much lower level of SETD2 and have
a lower level of H3K36me3 than SETD2-proficient cells, such as
NALM6 cells (Figure S4C). These observations suggest that
depletion of H3K36me3 promotes ccRCC and could play a
role in promoting other cancers (see Discussion).
Restoration of H3K36me3 in SETD2-Deficient Cells
Restores hMutSa Chromatin Localization
To further confirm that H3K36me3 facilitates recruitment of
hMutSa onto chromatin, we transiently transfected UOK143
cells with the yeast Set2 gene, which is known to efficiently pro-
mote H3K36 trimethylation in human cells (Luco et al., 2010).
Compared with control cells transfected with an empty vector,
Set2-expressing UOK143 cells exhibited higher levels of
H3K36me3, larger and more hMSH6 foci, and partial colocaliza-
tion of H3K36me3 and hMSH6. These observations are con-
sistent with the hypothesis that H3K36me3 recruits hMutSa
onto chromatin in vivo.
DISCUSSION
In this study, we demonstrate that H3K36me3 recruits hMutSa
to chromatin in a cell-cycle-dependent manner, such that
H3K36me3 and the histone methyltransferase SETD2 are
required for MMR in vivo. The finding provides a molecular
explanation for the lack of concurrence between the MSI pheno-
type and the MMR genotype among human cancer cells.
Although human MMR has been reconstituted in vitro (Con-
stantin et al., 2005; Zhang et al., 2005), little is known how the
MMR machinery operates on chromatin in vivo. The identifica-
tion of the hMSH6 PWWP domain as a reader of H3K36me3
prompted us to hypothesize that H3K36me3 recruits hMutSa
via this domain onto chromatin. We show here that (1) wild-type,Cell 153, 590–600, April 25, 2013 ª2013 Elsevier Inc. 595
Figure 6. Cancer Cells Defective in SETD2 Exhibit Classical MMR-Deficient Phenotype
(A) Western blot analysis of SETD2 and H3K36me3 in ccRCC cell lines UOK121 and UOK143.
(B) Nuclear localization of H3K36me3 and hMSH6 in ccRCC cell lines UOK121 and UOK143 in S phase.
(C) The number of hMSH6 foci per nucleus in UOK121 and UOK143 cells. The ‘‘n’’ value indicates the total number of nuclei analyzed in each case. The error bars
represent SD.
(D) PCR analysis of microsatellites BAT25, BAT26, and D5S346 in subclones of UOK121 and UOK143 cells. The red D or asterisk shows the clone exhibiting
deletion of a repeat mark or new repeat species, respectively.
(E) Nuclear localization of H3K36me3 and hMSH6 in UOK143 cells transfected with or without yeast Set2 in S phase.
See also Figure S4.but not mutant, hMSH6 PWWP domain interacts with
H3K36me3-containing histone octamers (Figure 2); (2) the
hMSH6 PWWP domain is essential for hMutSa chromatin local-
ization (Figure 3B); (3) cells depleted with H3K36me3 fail to
recruit hMutSa (Figures 3D, 4B, and 6B); (4) restoration of the
H3K36me3 signal also restores hMutSa chromatin localization in
SETD2-deficient cells (Figure 6E); and (5) SETD2/H3K36me3-
depleted cells display an MMR-deficient mutator phenotype
(Figures 5 and 6D). Therefore, H3K36me3 and the PWWP
domain regulate human MMR in vivo.
In support of this conclusion, the abundance of hMSH6 (and
hMutSa) foci in the nucleus of HeLa cells correlates with the
abundance of H3K36me3 during the cell cycle. The level of
H3K36me3 is highest in the early S phase, significantly declines
in themiddle S phase, and little remains in late S phase andG2/M
(Figure 4D), consistent with published results (Bonenfant et al.,
2007; Ryba et al., 2010). Correspondingly, hMSH6 foci are
readily seen in S phase but are rarely seen in G2/M (Figure 4C).
These results suggest that MMR is mainly active in S phase,
when it corrects DNA-replication-associated nucleotide misin-
corporations (Hombauer et al., 2011a, 2011b; Simmons et al.,
2008) but that hMutSa is likely recruited to chromatin before
DNA replication initiates. This appears to be consistent with a
recent yeast study. Despite that yeast MSH6 does not possess
a PWWP domain, and is probably not recruited to chromatin
by H3K36me3, Hombauer et al. (2011a) showed that yeast596 Cell 153, 590–600, April 25, 2013 ª2013 Elsevier Inc.MutSa is present at the replication fork, independent of the pres-
ence of mispaired bases. However, we provide evidence that
localizing hMutSa to chromatin, although essential for MMR
in vivo, is not sufficient to trigger or facilitate the biochemical re-
action of MMR in the context of chromatin, as judged by the fact
that a mismatch located between two histone octamers bearing
the H3K36me3 signature could not be corrected by MMR-
competent nuclear extracts (Figure S5), which also contain all
chromatin remodeling/modifying factors. This observation sug-
gests that the hMutSa recruitment to chromatin by H3K36me3
only sets up an on-call system for MMR, which is ready when-
ever it is needed, but triggering the MMR reaction needs both
specific mismatch signal and an environment of DNA replication,
which in part includes disassembly of nucleosome structure.
Based on previously published data and the results presented
here, we propose amodel for the initiation ofMMR in human cells
in vivo (Figure 7). First, the SETD2 methyltransferase converts
H3K36me2 to H3K36me3, either before or in early S phase.
Then, H3K36me3 helps recruit hMutSa onto chromatin through
its interaction with the hMSH6 PWWP domain. During DNA repli-
cation, nucleosomes are dynamically assembled and disas-
sembled, such that nucleosomes ahead of the replication fork
are disrupted and those behind the replication fork are rapidly
reassembled (Ransom et al., 2010). Nucleosome disassembly
provides the replication machinery access to DNA and at the
same time disrupts the H3K36me3-PWWP interaction, thereby
Figure 7. Model for hMutSa Recruitment to Chromatin and
Mismatched DNA
In the late G1 and/or early S phase, SETD2 converts H3K36me2 to H3K36me3.
H3K36me3 recruits hMutSa onto chromatin via its interaction with the hMSH6
PWWP domain before DNA replication initiates. During DNA replication,
nucleosome disassembly exposes naked DNA to the replication machinery
and also disrupts the H3K36me3-PWWP interaction, which releases hMutSa
from histone octamers. hMutSa, which has a strong DNA binding activity, can
readily bind to nascent DNA with or without an interaction with PCNA. Once a
mismatch is introduced, hMutSa can quickly identify the mismatch to initiate
the MMR reaction. See also Figure S5.releasing hMutSa from histone octamers. The released hMutSa
can then readily attach to temporarily histone-free nascent DNA
through its strong DNA binding activity and/or by interacting with
PCNA via the hMSH6 PIP (PCNA-interacting protein) box (Clark
et al., 2000; Flores-Rozas et al., 2000). hMutSa then slides along
the DNA helix (Gorman et al., 2007; Gradia et al., 1997; Mendillo
et al., 2005) to locate mispairs, which triggers downstream
events in the MMR pathway. However, mismatches assembled
in the nascent nucleosomes behind the replication fork will not
be repaired (Figure S5).
It is worth mentioning that both the human and yeast MSH6
PIP boxes have been shown to be required forMutSa colocaliza-
tion with replication factories (Hombauer et al., 2011a; Klecz-
kowska et al., 2001). Interestingly, depletion of the PIP box
only moderately (10%–15%) reduces MMR activity in yeast
(Hombauer et al., 2011a; Shell et al., 2007) and does not abolish
hMSH6 foci formation in human cells (Kleczkowska et al., 2001).
These observations indicate that PIP-defective MutSa can still
be efficiently recruited to chromatin. We therefore propose that
in human cells, the hMSH6 PIP box and PWWP domain are likely
to play different but complementary roles in MMR. One possibil-
ity is that the PWWP domain localizes hMutSa to H3K36me3-
containing chromatin before replication initiates and then thePIP box helps localize hMutSa to newly formedmispairs through
its interaction with PCNA during DNA replication. This could also
explain the presence of a fraction of hMSH6 foci that do not
colocalize with H3K36me3 foci in S phase (Figures 4B, 6B, 6E,
and S1). Further investigations are needed to explore this and
other possibilities.
The data presented here suggest that tumors defective in
SETD2 fail to recruit hMutSa to chromatin and therefore are
MMRdeficient in vivo. Recently, a number of exome-sequencing
studies have identified SETD2 mutations in ccRCC (Dalgliesh
et al., 2010; Duns et al., 2010; Gerlinger et al., 2012; Varela
et al., 2011), lung cancer (Govindan et al., 2012; Imielinski et al.,
2012), and hematological malignancies (Zhang et al., 2012).
These SETD2-deficient cancers have no detectable mutations
in MMR genes; however, results presented here are consistent
with the idea that SETD2 mutations are responsible for an MMR
defect in these cells. Notably, all SETD2-deficient ccRCC tumors
have a high frequency of small insertion-deletion mutations and
dominant single-nucleotide substitutions (Dalgliesh et al., 2010;
Gerlinger et al., 2012), which are hallmarks of MMR deficiency.
In addition, a subset of gastric cancers that display MSI have
no mutations in known MMR genes but are defective in SETD2
(Wang et al., 2011). A similar situation may exist in some MSI-
positive colorectal cancer cells (Peltoma¨ki, 2003).
H3K36me3 interacts with multiple PWWP-containing proteins
in vivo, and the importance of H3K36me3 in transcriptional regu-
lation is well documented (Musselman et al., 2012). How is the
dual impact of H3K36me3 on MMR and transcription regulated
or partitioned? Because MMR is not active in G1, it remains to
be investigated if the observed hMSH6-H3K36me3 interaction
in G1 (Figure S1B) facilitates transcription or occurs just before
cells enter S phase (note that double-thymidine treatment
arrests the cell cycle at the G1-S boundary). Because MMR is
coupled to DNA replication, MMR and transcription could only
compete with one another for H3K36me3 during S phase.
Although an as-yet-unknown mechanism may avoid such
competition, Wansink et al. (1994) have already shown that
transcription and replication rarely occur at the same time in
the same place in S phase nuclei. If universally true, then there
is little risk of conflict between roles for H3K36me3 in MMR
and transcription.
In summary, we demonstrate that H3K36me3 regulates MMR
in vivo. This striking finding underscores the importance of the
histone code in maintaining genome stability. Recent studies
reveal that mutation rates in cancer genomes are closely
related to histone modification-directed chromatin organization
(Schuster-Bo¨ckler and Lehner, 2012). In that regard, future
studies may reveal that the abundance of H3K36me3 in a gene
or gene regulatory region plays a role in determining the muta-
bility of that segment of the human genome.
EXPERIMENTAL PROCEDURES
Cell Lines
HeLa, NALM6, andNAMALWAcells were grown in RPMI1640medium supple-
mented with 10% fetal bovine serum (FBS). UOK121, UOK143, and DLD-1
cells were maintained in Dulbecco’s modified Eagle’s medium with 10%
FBS. The stable SETD2 knockdown HeLa (shSETD2-HeLa) and SETD2 knock-
down DLD-1 lines were created by lentivirus (Sigma-Aldrich, St. Louis)Cell 153, 590–600, April 25, 2013 ª2013 Elsevier Inc. 597
transfection under puromycin selection in accordance with the manufacturer’s
instructions.
Protein and Peptide Preparations
Human wild-type and mutant MutSa proteins were expressed and purified as
described previously (Zhang et al., 2005). The hMSH6 gene used for muta-
genesis was a gift of Dr. Richard Kolodner. For expression of GST-PWWP
fusion peptides, wild-type and mutant PWWP domain fragments of hMSH6
were PCR amplified and cloned into pGEX4T2 (GE Healthcare Life Sciences,
Waukesha, WI, USA). After verification by sequencing, the resulting plasmids
were used for protein expression and purification from an Escherichia coli
Rosetta (DE3) strain (Novagen, San Diego). Recombinant H2A, H2B, H3, and
H4 were obtained, and histone octamers were assembled as described previ-
ously (Li et al., 2009). Native histone octamers were isolated fromHeLa cells as
described previously (Rodriguez-Collazo et al., 2009). EGFP-hMSH6 expres-
sion vector (pEGFP-C1-hMSH6, a gift of Dr. Akira Yasui) was used to generate
the expression vectors of EGFP-hMSH6-PAAP, EGFP-hMSH6-Y103A, and
EGFP-hMSH6-F133A. Histone H3 peptides (ARKSAPATGGVK36KPHRYRP)
containing various forms of K36 methylation were commercially synthesized
(GenScript, Piscataway, NJ, USA).
MSI and HPRTMutability Analyses
For each cell line tested for MSI, independent single cell colonies were isolated
in 96-well microtiter plates, and genomic DNAwas isolated. Fourmicrosatellite
markers (BAT25, BAT26, D2S123, and D5S346) were used for MSI analysis
(Parsons et al., 1993).
TheHPRTmutation assaywas conducted as described previously (Kat et al.,
1993). Cells (5 3 105) were seeded in triplicate 100 mm Petri dishes for 12 hr
and fedwith completemediumcontaining 5 mMfreshly prepared 6-thioguanine
(6-TG). The plating efficiency was determined by culturing 5 3 102 cells
similarly in the absence of 6-TG. After 10 days of culturing, cell colonies were
visualized by staining with 0.05% crystal violet. The mutation frequency was
determined by dividing the number of 6-TG-resistant colonies by the total
number of cells plated after being corrected for the colony-forming ability.
Cell Synchronization and Cell-Cycle Analysis
Cell synchronization was performed as described previously (Stojic et al.,
2004). Cells were arrested at G1/S by culturing for 18 hr in complete medium
containing 2 mM thymidine, 10 hr in thymidine-free medium, and then
thymidine-containing medium for an additional 15 hr before release into
complete medium. Cells were harvested at 0 hr (G1 phase), 1 hr (early S),
2.5 hr (middle S), 4 hr (late S), and 8 hr (G2/M). Cell-cycle status was confirmed
by flow cytometry.
Microscopy and Immunofluorescence Analysis
Immunofluorescence analysis was performed essentially as described previ-
ously (Kleczkowska et al., 2001). Fluorescence images were obtained and
analyzed using an FV-1000 Olympus confocal scanning laser microscopy
system. The percentage of colocalized H3K36me3 and hMSH6 foci was
quantified using the Olympus FV10-ASW2.1 software, based on analyzing
the Pearson correlation coefficient as described previously (Adler and
Parmryd, 2010).
Mismatch Repair Assay
In vitro MMR assays were performed as described previously (Holmes et al.,
1990; Zhang et al., 2005). Unless otherwise specified, MMR activity was
determined in a 20 ml reaction containing 50 mg of nuclear extracts and
100 ng of a circular DNA substrate containing a G-T mismatch in the presence
or absence of hMutSa. The reaction was incubated at 37C for 15 min, and
repair was scored and analyzed by restriction enzyme digestions and agarose
gel electrophoresis.
Western Blot, Coimmunoprecipitation, and Pull-Down Assays
Antibodies used in this study were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA) (MSH2, MSH3, histone H3, GST, and tubulin), BD
Biosciences (Franklin Lakes, NJ, USA) (MSH6), Sigma-Aldrich (SETD2), and
Cell Signaling Technology (Danvers, MA, USA) (SETD2 and H3K36me3).598 Cell 153, 590–600, April 25, 2013 ª2013 Elsevier Inc.Statistical Analysis
All statistical assays, Student’s t test, and one-way analysis of variance
(ANOVA) with Tukey’s multiple comparison were performed using GraphPad
Prism 5.0 (GraphPad Software, LaJolla, CA, USA). Data were considered
statistically significant if p values were less than 0.05 or 0.001, as indicated.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and can be found with this
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ACKNOWLEDGMENTS
We thank Richard Kolodner, Tom Misteli, Jeffrey Parvin, Youfeng Yang, and
Akira Yasui for reagents and Yang Shi, Dangsheng Li, Charles Ensor, and
Nathan Vanderford for stimulating discussions and helpful comments. This
work was supported in part by grants from the National Institutes of Health
(CA167181, CA115942, and GM089684 to G.-M.L.) (CA104333 to L.G.), the
National Institute of Diabetes and Digestive and Kidney Diseases intramural
research fund (to W.Y.), and a grant from the Kentucky Lung Cancer Research
Program. G.-M.L. holds the James-Gardner Chair in Cancer Research.
Received: September 25, 2012
Revised: February 13, 2013
Accepted: March 18, 2013
Published: April 25, 2013
REFERENCES
Adler, J., and Parmryd, I. (2010). Quantifying colocalization by correlation: the
Pearson correlation coefficient is superior to the Mander’s overlap coefficient.
Cytometry A 77, 733–742.
Bonenfant, D., Towbin, H., Coulot, M., Schindler, P., Mueller, D.R., and van
Oostrum, J. (2007). Analysis of dynamic changes in post-translational
modifications of human histones during cell cycle by mass spectrometry.
Mol. Cell. Proteomics 6, 1917–1932.
Clark, A.B., Valle, F., Drotschmann, K., Gary, R.K., and Kunkel, T.A. (2000).
Functional interaction of proliferating cell nuclear antigen with MSH2-MSH6
and MSH2-MSH3 complexes. J. Biol. Chem. 275, 36498–36501.
Constantin, N., Dzantiev, L., Kadyrov, F.A., and Modrich, P. (2005). Human
mismatch repair: reconstitution of a nick-directed bidirectional reaction.
J. Biol. Chem. 280, 39752–39761.
Dalgliesh, G.L., Furge, K., Greenman, C., Chen, L., Bignell, G., Butler, A.,
Davies, H., Edkins, S., Hardy, C., Latimer, C., et al. (2010). Systematic
sequencing of renal carcinoma reveals inactivation of histone modifying
genes. Nature 463, 360–363.
Dhayalan, A., Rajavelu, A., Rathert, P., Tamas, R., Jurkowska, R.Z., Ragozin,
S., and Jeltsch, A. (2010). The Dnmt3a PWWP domain reads histone 3
lysine 36 trimethylation and guides DNA methylation. J. Biol. Chem. 285,
26114–26120.
Drummond, J.T., Li, G.M., Longley, M.J., and Modrich, P. (1995). Isolation of
an hMSH2-p160 heterodimer that restores DNA mismatch repair to tumor
cells. Science 268, 1909–1912.
Drummond, J.T., Genschel, J., Wolf, E., and Modrich, P. (1997). DHFR/MSH3
amplification inmethotrexate-resistant cells alters the hMutSalpha/hMutSbeta
ratio and reduces the efficiency of base-base mismatch repair. Proc. Natl.
Acad. Sci. USA 94, 10144–10149.
Duns, G., van den Berg, E., van Duivenbode, I., Osinga, J., Hollema, H.,
Hofstra, R.M., and Kok, K. (2010). Histone methyltransferase gene SETD2 is
a novel tumor suppressor gene in clear cell renal cell carcinoma. Cancer
Res. 70, 4287–4291.
Edmunds, J.W., Mahadevan, L.C., and Clayton, A.L. (2008). Dynamic histone
H3 methylation during gene induction: HYPB/Setd2 mediates all H3K36
trimethylation. EMBO J. 27, 406–420.
Fishel, R., and Kolodner, R.D. (1995). Identification of mismatch repair genes
and their role in the development of cancer. Curr. Opin. Genet. Dev. 5,
382–395.
Flores-Rozas, H., Clark, D., and Kolodner, R.D. (2000). Proliferating cell
nuclear antigen and Msh2p-Msh6p interact to form an active mispair recogni-
tion complex. Nat. Genet. 26, 375–378.
Gerlinger, M., Rowan, A.J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos,
E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012). Intratumor
heterogeneity and branched evolution revealed by multiregion sequencing.
N. Engl. J. Med. 366, 883–892.
Gorman, J., Chowdhury, A., Surtees, J.A., Shimada, J., Reichman, D.R., Alani,
E., and Greene, E.C. (2007). Dynamic basis for one-dimensional DNA scanning
by the mismatch repair complex Msh2-Msh6. Mol. Cell 28, 359–370.
Govindan, R., Ding, L., Griffith, M., Subramanian, J., Dees, N.D., Kanchi, K.L.,
Maher, C.A., Fulton, R., Fulton, L., Wallis, J., et al. (2012). Genomic landscape
of non-small cell lung cancer in smokers and never-smokers. Cell 150,
1121–1134.
Gradia, S., Acharya, S., and Fishel, R. (1997). The human mismatch recogni-
tion complex hMSH2-hMSH6 functions as a novel molecular switch. Cell 91,
995–1005.
Gu, L., Cline-Brown, B., Zhang, F., Qiu, L., and Li, G.M. (2002). Mismatch repair
deficiency in hematological malignancies with microsatellite instability.
Oncogene 21, 5758–5764.
Harrington, J.M., and Kolodner, R.D. (2007). Saccharomyces cerevisiaeMsh2-
Msh3 acts in repair of base-base mispairs. Mol. Cell. Biol. 27, 6546–6554.
Holmes, J., Jr., Clark, S., and Modrich, P. (1990). Strand-specific mismatch
correction in nuclear extracts of human and Drosophila melanogaster cell
lines. Proc. Natl. Acad. Sci. USA 87, 5837–5841.
Hombauer, H., Campbell, C.S., Smith, C.E., Desai, A., and Kolodner, R.D.
(2011a). Visualization of eukaryotic DNA mismatch repair reveals distinct
recognition and repair intermediates. Cell 147, 1040–1053.
Hombauer, H., Srivatsan, A., Putnam, C.D., and Kolodner, R.D. (2011b).
Mismatch repair, but not heteroduplex rejection, is temporally coupled to
DNA replication. Science 334, 1713–1716.
Hong, Z., Jiang, J., Hashiguchi, K., Hoshi, M., Lan, L., and Yasui, A. (2008).
Recruitment of mismatch repair proteins to the site of DNA damage in human
cells. J. Cell Sci. 121, 3146–3154.
Imielinski, M., Berger, A.H., Hammerman, P.S., Hernandez, B., Pugh, T.J.,
Hodis, E., Cho, J., Suh, J., Capelletti, M., Sivachenko, A., et al. (2012).Mapping
the hallmarks of lung adenocarcinomawithmassively parallel sequencing. Cell
150, 1107–1120.
Javaid, S., Manohar, M., Punja, N., Mooney, A., Ottesen, J.J., Poirier, M.G.,
and Fishel, R. (2009). Nucleosome remodeling by hMSH2-hMSH6. Mol. Cell
36, 1086–1094.
Kadyrova, L.Y., Blanko, E.R., and Kadyrov, F.A. (2011). CAF-I-dependent
control of degradation of the discontinuous strands during mismatch repair.
Proc. Natl. Acad. Sci. USA 108, 2753–2758.
Kane, M.F., Loda, M., Gaida, G.M., Lipman, J., Mishra, R., Goldman, H.,
Jessup, J.M., and Kolodner, R. (1997). Methylation of the hMLH1 promoter
correlates with lack of expression of hMLH1 in sporadic colon tumors and
mismatch repair-defective human tumor cell lines. Cancer Res. 57, 808–811.
Kat, A., Thilly, W.G., Fang, W.H., Longley, M.J., Li, G.M., and Modrich, P.
(1993). An alkylation-tolerant, mutator human cell line is deficient in strand-
specific mismatch repair. Proc. Natl. Acad. Sci. USA 90, 6424–6428.
Kleczkowska, H.E., Marra, G., Lettieri, T., and Jiricny, J. (2001). hMSH3 and
hMSH6 interact with PCNA and colocalize with it to replication foci. Genes
Dev. 15, 724–736.
Kolodner, R. (1996). Biochemistry and genetics of eukaryotic mismatch repair.
Genes Dev. 10, 1433–1442.
Kunkel, T.A., and Erie, D.A. (2005). DNAmismatch repair. Annu. Rev. Biochem.
74, 681–710.Laguri, C., Duband-Goulet, I., Friedrich, N., Axt, M., Belin, P., Callebaut, I.,
Gilquin, B., Zinn-Justin, S., and Couprie, J. (2008). Human mismatch repair
protein MSH6 contains a PWWP domain that targets double stranded DNA.
Biochemistry 47, 6199–6207.
Li, G.M. (2008). Mechanisms and functions of DNA mismatch repair. Cell Res.
18, 85–98.
Li, F., Tian, L., Gu, L., and Li, G.M. (2009). Evidence that nucleosomes inhibit
mismatch repair in eukaryotic cells. J. Biol. Chem. 284, 33056–33061.
Luco, R.F., Pan, Q., Tominaga, K., Blencowe, B.J., Pereira-Smith, O.M., and
Misteli, T. (2010). Regulation of alternative splicing by histone modifications.
Science 327, 996–1000.
Marra, G., Iaccarino, I., Lettieri, T., Roscilli, G., Delmastro, P., and Jiricny, J.
(1998). Mismatch repair deficiency associated with overexpression of the
MSH3 gene. Proc. Natl. Acad. Sci. USA 95, 8568–8573.
Marsischky, G.T., Filosi, N., Kane, M.F., and Kolodner, R. (1996). Redundancy
of Saccharomyces cerevisiae MSH3 and MSH6 in MSH2-dependent
mismatch repair. Genes Dev. 10, 407–420.
Mendillo, M.L., Mazur, D.J., and Kolodner, R.D. (2005). Analysis of the interac-
tion between the Saccharomyces cerevisiae MSH2-MSH6 and MLH1-PMS1
complexes with DNA using a reversible DNA end-blocking system. J. Biol.
Chem. 280, 22245–22257.
Modrich, P., and Lahue, R. (1996). Mismatch repair in replication fidelity,
genetic recombination, and cancer biology. Annu. Rev. Biochem. 65, 101–133.
Musselman, C.A., Lalonde, M.E., Coˆte´, J., and Kutateladze, T.G. (2012).
Perceiving the epigenetic landscape through histone readers. Nat. Struct.
Mol. Biol. 19, 1218–1227.
Parsons, R., Li, G.M., Longley, M.J., Fang,W.H., Papadopoulos, N., Jen, J., de
la Chapelle, A., Kinzler, K.W., Vogelstein, B., and Modrich, P. (1993).
Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell
75, 1227–1236.
Peltoma¨ki, P. (2003). Role of DNAmismatch repair defects in the pathogenesis
of human cancer. J. Clin. Oncol. 21, 1174–1179.
Ransom, M., Dennehey, B.K., and Tyler, J.K. (2010). Chaperoning histones
during DNA replication and repair. Cell 140, 183–195.
Rodriguez-Collazo, P., Leuba, S.H., and Zlatanova, J. (2009). Robust methods
for purification of histones from cultured mammalian cells with the preserva-
tion of their native modifications. Nucleic Acids Res. 37, e81.
Ryba, T., Hiratani, I., Lu, J., Itoh, M., Kulik, M., Zhang, J., Schulz, T.C., Robins,
A.J., Dalton, S., and Gilbert, D.M. (2010). Evolutionarily conserved replication
timing profiles predict long-range chromatin interactions and distinguish
closely related cell types. Genome Res. 20, 761–770.
Scho¨pf, B., Bregenhorn, S., Quivy, J.P., Kadyrov, F.A., Almouzni, G., and
Jiricny, J. (2012). Interplay between mismatch repair and chromatin assembly.
Proc. Natl. Acad. Sci. USA 109, 1895–1900.
Schuster-Bo¨ckler, B., and Lehner, B. (2012). Chromatin organization is amajor
influence on regional mutation rates in human cancer cells. Nature 488,
504–507.
Shell, S.S., Putnam, C.D., and Kolodner, R.D. (2007). The N terminus
of Saccharomyces cerevisiae Msh6 is an unstructured tether to PCNA. Mol.
Cell 26, 565–578.
Simmons, L.A., Davies, B.W., Grossman, A.D., and Walker, G.C. (2008). Beta
clamp directs localization of mismatch repair in Bacillus subtilis. Mol. Cell 29,
291–301.
Simon, M.D., Chu, F., Racki, L.R., de la Cruz, C.C., Burlingame, A.L., Panning,
B., Narlikar, G.J., and Shokat, K.M. (2007). The site-specific installation of
methyl-lysine analogs into recombinant histones. Cell 128, 1003–1012.
Stojic, L., Mojas, N., Cejka, P., Di Pietro, M., Ferrari, S., Marra, G., and Jiricny,
J. (2004). Mismatch repair-dependent G2 checkpoint induced by low doses
of SN1 type methylating agents requires the ATR kinase. Genes Dev. 18,
1331–1344.
Thomas, D.C., Roberts, J.D., and Kunkel, T.A. (1991). Heteroduplex repair in
extracts of human HeLa cells. J. Biol. Chem. 266, 3744–3751.Cell 153, 590–600, April 25, 2013 ª2013 Elsevier Inc. 599
Umar, A., Boyer, J.C., Thomas, D.C., Nguyen, D.C., Risinger, J.I., Boyd, J.,
Ionov, Y., Perucho, M., and Kunkel, T.A. (1994). Defective mismatch repair in
extracts of colorectal and endometrial cancer cell lines exhibiting microsatel-
lite instability. J. Biol. Chem. 269, 14367–14370.
Varela, I., Tarpey, P., Raine, K., Huang, D., Ong, C.K., Stephens, P., Davies, H.,
Jones, D., Lin, M.L., Teague, J., et al. (2011). Exome sequencing identifies
frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma.
Nature 469, 539–542.
Vermeulen, M., Eberl, H.C., Matarese, F., Marks, H., Denissov, S., Butter, F.,
Lee, K.K., Olsen, J.V., Hyman, A.A., Stunnenberg, H.G., and Mann, M.
(2010). Quantitative interaction proteomics and genome-wide profiling of
epigenetic histone marks and their readers. Cell 142, 967–980.
Vezzoli, A., Bonadies, N., Allen, M.D., Freund, S.M., Santiveri, C.M., Kvinlaug,
B.T., Huntly, B.J., Go¨ttgens, B., and Bycroft, M. (2010). Molecular basis of
histone H3K36me3 recognition by the PWWP domain of Brpf1. Nat. Struct.
Mol. Biol. 17, 617–619.
Wang, K., Kan, J., Yuen, S.T., Shi, S.T., Chu, K.M., Law, S., Chan, T.L., Kan, Z.,
Chan, A.S., Tsui, W.Y., et al. (2011). Exome sequencing identifies frequent600 Cell 153, 590–600, April 25, 2013 ª2013 Elsevier Inc.mutation of ARID1A in molecular subtypes of gastric cancer. Nat. Genet. 43,
1219–1223.
Wansink, D.G., Manders, E.E., van der Kraan, I., Aten, J.A., van Driel, R., and
de Jong, L. (1994). RNA polymerase II transcription is concentrated outside
replication domains throughout S-phase. J. Cell Sci. 107, 1449–1456.
Wu, H., Zeng, H., Lam, R., Tempel, W., Amaya, M.F., Xu, C., Dombrovski, L.,
Qiu, W., Wang, Y., and Min, J. (2011). Structural and histone binding ability
characterizations of human PWWP domains. PLoS ONE 6, e18919.
Yoh, S.M., Lucas, J.S., and Jones, K.A. (2008). The Iws1:Spt6:CTD complex
controls cotranscriptional mRNA biosynthesis and HYPB/Setd2-mediated
histone H3K36 methylation. Genes Dev. 22, 3422–3434.
Zhang, Y., Yuan, F., Presnell, S.R., Tian, K., Gao, Y., Tomkinson, A.E., Gu, L.,
and Li, G.M. (2005). Reconstitution of 50-directed human mismatch repair in a
purified system. Cell 122, 693–705.
Zhang, J., Ding, L., Holmfeldt, L., Wu, G., Heatley, S.L., Payne-Turner, D.,
Easton, J., Chen, X., Wang, J., Rusch, M., et al. (2012). The genetic basis of
early T-cell precursor acute lymphoblastic leukaemia. Nature 481, 157–163.
